Form 4: Avalo CFO Sells Shares for Tax, Boosts ESPP Holdings

Avalo Therapeutics' CFO, Christopher Sullivan, reported a disposition of 155 shares for tax purposes and an acquisition of 417 shares via the Employee Stock Purchase Plan, effective December 10, 2025.

Summary

• Christopher Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc. (AVTX), reported changes in his beneficial ownership of common stock.
• On December 10, 2025, Sullivan disposed of 155 shares of common stock at a price of $4.1 per share. This transaction was coded 'F', indicating it was for the payment of exercise price or tax liability.
• Concurrently, Sullivan acquired 417 additional shares through the Issuer's Employee Stock Purchase Plan (ESPP).
• Following these reported transactions, Sullivan's total beneficial ownership of Avalo Therapeutics common stock stands at 17,338 shares.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider transaction involving both a disposition for tax purposes and an acquisition through an employee plan, resulting in a net increase in holdings. The reported transaction date of December 10, 2025, is unusual as it is in the future, but this does not inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of 417 shares through the Employee Stock Purchase Plan indicates continued participation and investment by the CFO in the company's equity.

Negatives

• The disposition of 155 shares, even if for tax purposes, represents a reduction in direct holdings.

Risks

• The filing reports a transaction date of December 10, 2025, which is a future date, raising questions about the accuracy or nature of the reported event.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, beyond the future transaction date itself.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, common across all publicly traded companies. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector, but rather reflects an individual executive's equity management.

Stakeholder Impact

• Shareholders: The CFO's net increase in holdings (417 acquired via ESPP vs. 155 disposed for tax) could be seen as a minor positive signal of management's continued belief in the company.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CFO disposed of a small number of shares for tax purposes while simultaneously acquiring more shares through an employee stock purchase plan, resulting in a net increase in his overall holdings. Such a transaction is generally neutral in its implications for the company's fundamental value or future prospects. It does not provide new information warranting a change in investment thesis, hence a 'hold' recommendation is appropriate.

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Trading, Stock Transaction, CFO, Christopher Sullivan, Employee Stock Purchase Plan, ESPP, Beneficial Ownership